Haut B, Karamaoun C, Rigaut C
PLoS One. 2025; 20(1):e0311667.
PMID: 39883668
PMC: 11781630.
DOI: 10.1371/journal.pone.0311667.
Tiwari A, Hobbs B, Sharma R, Li J, Kho A, Amr S
Respir Res. 2025; 26(1):38.
PMID: 39856653
PMC: 11763123.
DOI: 10.1186/s12931-025-03116-w.
Fainardi V, Grandinetti R, Mussi N, Rossi A, Masetti M, Giudice A
Respir Res. 2024; 25(1):445.
PMID: 39731113
PMC: 11674617.
DOI: 10.1186/s12931-024-03078-5.
Ali A, Rasheed H, Ansari S, Ansari S, Alkahtani H
Pharmaceuticals (Basel). 2024; 17(11).
PMID: 39598467
PMC: 11597469.
DOI: 10.3390/ph17111558.
Plichta J, Majos A, Kuna P, Panek M
Exp Ther Med. 2024; 28(6):445.
PMID: 39386939
PMC: 11462400.
DOI: 10.3892/etm.2024.12735.
Exercise-Induced Bronchoconstriction in Children: State of the Art from Diagnosis to Treatment.
Grandinetti R, Mussi N, Rossi A, Zambelli G, Masetti M, Giudice A
J Clin Med. 2024; 13(15).
PMID: 39124824
PMC: 11312884.
DOI: 10.3390/jcm13154558.
Bronchial Asthma and COVID-19: Etiology, Pathological Triggers, and Therapeutic Considerations.
Starshinova A, Borozinets A, Kulpina A, Sereda V, Rubinstein A, Kudryavtsev I
Pathophysiology. 2024; 31(2):269-287.
PMID: 38921725
PMC: 11206645.
DOI: 10.3390/pathophysiology31020020.
Efficacy and safety of mepolizumab in a Chinese population with severe asthma: a phase III, randomised, double-blind, placebo-controlled trial.
Chen R, Wei L, Dai Y, Wang Z, Yang D, Jin M
ERJ Open Res. 2024; 10(3).
PMID: 38770009
PMC: 11103715.
DOI: 10.1183/23120541.00750-2023.
Ratio of plasma IL-13/TNF- ∝ and CXCL10/CCL17 predicts mepolizumab and omalizumab response in asthma better than eosinophil count or immunoglobulin E level.
Akenroye A, Nopsopon T, Hacker J, Laidlaw T
Sci Rep. 2024; 14(1):10404.
PMID: 38710930
PMC: 11074109.
DOI: 10.1038/s41598-024-60864-3.
[Recent research on the relationship between pulmonary microbiome and asthma endotypes in children].
Li J
Zhongguo Dang Dai Er Ke Za Zhi. 2023; 25(10):1078-1083.
PMID: 37905767
PMC: 10621051.
DOI: 10.7499/j.issn.1008-8830.2304056.
Age at asthma diagnosis and onset of symptoms among adults with allergic and non-allergic asthma.
Pakkasela J, Salmela P, Juntunen P, Karjalainen J, Lehtimaki L
Eur Clin Respir J. 2023; 10(1):2269653.
PMID: 37869726
PMC: 10586087.
DOI: 10.1080/20018525.2023.2269653.
Advances in the pathogenesis and personalised treatment of paediatric asthma.
Scotney E, Fleming L, Saglani S, Sonnappa S, Bush A
BMJ Med. 2023; 2(1):e000367.
PMID: 37841968
PMC: 10568124.
DOI: 10.1136/bmjmed-2022-000367.
Definition, Phenotyping of Severe Asthma, Including Cluster Analysis.
Casanova S, Ahmed E, Bourdin A
Adv Exp Med Biol. 2023; 1426:239-252.
PMID: 37464124
DOI: 10.1007/978-3-031-32259-4_11.
The Efficacy of an Oral Formulation of , , and as an Add-on Therapy for Mild-to-moderate Childhood Asthma: A Randomized Placebo-Controlled Clinical Trial.
Rabbani F, Raeisi M, Keivanfar M, Saffaei A, Sabzghabaee A
J Res Pharm Pract. 2023; 11(3):116-123.
PMID: 37304220
PMC: 10252578.
DOI: 10.4103/jrpp.jrpp_77_22.
Management of eosinophil-associated inflammatory diseases: the importance of a multidisciplinary approach.
Quirce S, Cosio B, Espana A, Blanco R, Mullol J, Santander C
Front Immunol. 2023; 14:1192284.
PMID: 37266434
PMC: 10229838.
DOI: 10.3389/fimmu.2023.1192284.
New insights into the pathophysiology and therapeutic targets of asthma and comorbid chronic rhinosinusitis with or without nasal polyposis.
Striz I, Golebski K, Strizova Z, Loukides S, Bakakos P, Hanania N
Clin Sci (Lond). 2023; 137(9):727-753.
PMID: 37199256
PMC: 10195992.
DOI: 10.1042/CS20190281.
Phenotype overlap in the natural history of asthma.
Ricciardolo F, Guida G, Bertolini F, Di Stefano A, Carriero V
Eur Respir Rev. 2023; 32(168).
PMID: 37197769
PMC: 10189644.
DOI: 10.1183/16000617.0201-2022.
Store-operated calcium entry enhances the polarization and chemotaxis of neutrophils in the peripheral venous blood of patients with bronchial asthma by upregulating ERM protein.
Deng F, Yu C, Zhong S, Liang Z, Lin C, Zou F
J Thorac Dis. 2023; 15(4):2051-2067.
PMID: 37197551
PMC: 10183558.
DOI: 10.21037/jtd-23-467.
Progress in non-viral localized delivery of siRNA therapeutics for pulmonary diseases.
Gao J, Xia Z, Vohidova D, Joseph J, Luo J, Joshi N
Acta Pharm Sin B. 2023; 13(4):1400-1428.
PMID: 37139423
PMC: 10150162.
DOI: 10.1016/j.apsb.2022.07.010.
Cytokine-targeted therapies for asthma and COPD.
Schleich F, Bougard N, Moermans C, Sabbe M, Louis R
Eur Respir Rev. 2023; 32(168).
PMID: 37076177
PMC: 10113955.
DOI: 10.1183/16000617.0193-2022.